Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca® (rucaparib) is now available and reimbursed in France.

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca® (rucaparib) is now available and reimbursed in France.

Rucaparib is an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy. Rucaparib is indicated for eligible patients regardless of BRCA status, which means it can be prescribed for women who harbor a BRCA mutation or who are BRCA wild-type.

·       Approximately 5,000 women are diagnosed with ovarian cancer in France every year, which equates to roughly 14 every day.

·       Ovarian cancer is the eighth most common cancer in women and the fourth most fatal cancer in France.

·       Approximately 25 percent of ovarian cancer patients harbor a BRCA1/2 mutation in the tumour, correlating to improved outcomes to platinum and PARP inhibitors therapy.

Attached is the CLVS press release on this announcement and following are links to a Clovis Clinical Trials Overview and a Ovarian cancer in Europe infographic.